| |
|
|
Meeting
calls new attention to LASIK research directions
Femtosecond laser corneal flap with a roster pattern to create a superior
hinge
Source: Dimitri Azar, M.D.
Intra-op image of corneal stroma during excimer laser treatment after flap
lift
Source : Dimitri Azar, M.D.

Laser ablation with the Allegretto and flap creation with the IntraLase
Source: Daniel S. Durrie, M.D
The Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel
meeting regarding LASIK in April thrust the popular surgical procedure
into the spotlight.
Although numerous studies have proven LASIK to be safe and effective,
many believe it still can benefit from further research to bolster the
procedure,
Previous studies have enabled surgeons to reduce night-vision problems
such as glare and haloes, said Daniel S. Durrie, M.D., clinical professor
of ophthalmology, University of Kansas, Overland Park. Research also
has led to increased use of wavefront technology, making LASIK even more
personalized to the patient’s visual needs.
Now, clinicians can turn their attention to issues such as managing dry
eye, reducing ectasia, and testing LASIK’s limits in unique population
groups, surgeons said.
Dry eye and LASIK
“The LASIK population by nature is drier because they can’t
wear contacts,” Dr. Durrie said—but this is why they opted
for surgery in place of contact lenses in the first place. “This
is an area where we need to continue to evaluate patients pre-operatively
with technology today and continue to develop better technology.”
Even though Dr. Durrie said not all surgeons believe that LASIK itself
causes dry eye, many agree that the procedure can aggravate the ocular
surface. As awareness of dry eye grows, research on the best ways to
test patients for dry eye before surgery and a comparison of regimens
that treat dry eye pre-op or post-op would benefit the field, surgeons
said.
“There are a significant number of patients dissatisfied with dry-eye
symptoms that don’t always show up on clinical tests. We’re
learning to focus on this more,” said Richard L. Lindstrom, M.D.,
adjunct professor emeritus, University of Minnesota, Minneapolis.
Studies that demonstrate the value of using a medication like cyclosporine
(ophthalmic emulsion, Restasis, Allergan, Irvine, Calif.) before and
after surgery in all patients would assist in the goal to return patients
back to normal visual function as soon as possible, said David Tanzer,
M.D., director of the Navy refractive surgery program, San Diego.
Studies of pre-op treatment with omega-3 oils and better lid hygiene
for better blepharitis patients would also expand the dry-eye/LASIK research
arena, Dr. Durrie added.
Ectasia
The occurrence of post-LASIK ectasia deserves further study, Dr. Durrie
believes. This research could cover patient screening and whether or
not it is indeed ectasia that occurs after LASIK and not something else.
“”I think these [post-LASIK ectasia cases] are all keratoconus,” Dr.
Durrie said. “I think it’s exceedingly rare that you would
cause a normal cornea to get ectatic. I don’t think there’s
evidence that we’re creating that, but I do think we’re not
doing a good enough job to continue to screen for keratoconus patients
and do good informed consent.”
This is where recent reports of corneal cross-linking, which stiffens
the cornea, could help, Dr. Durrie said.
The development of genetic tests that would help determine patients at
risk for keratoconus also could help steer suspect patients away from
LASIK, he said.
Better ways to determine patients’ risk for post-op ectasia is
an area ripe for future research, Dr. Durrie said. Although some recent
studies in this area helped to generate thinking on this topic, Dr. Durrie
would like to see more work.
LASIK in unique populations
The safety and efficacy of LASIK in a number of unique patient groups
is another area that needs exploration, believes Steven C. Schallhorn,
M.D., San Diego, and chief medical director, Optical Express, London.
This includes both patient groups that were always assumed to be poor
candidates for LASIK as well as groups that may have had trouble with
LASIK originally but now may benefit from the surgery’s evolution.
Anecdotal evidence and smaller studies are showing that patients with
certain stable disease conditions such as diabetes or well-controlled
autoimmune conditions like rheumatoid arthritis and systemic lupus may
be adequate LASIK candidates, Dr. Schallhorn said. However, because these
patients generally have not been included in the FDA trials for the lasers,
these conditions are listed as relative or absolute contraindications
for LASIK.
“Maybe this contraindication isn’t a contraindication. Further
study would be useful,” he said. “This is a group of patients
who may benefit from LASIK but who are turned away.”
Other patients who deserve special study are quadriplegic and paraplegic
patients who cannot wear contact lenses and need assistance wearing glasses,
Dr. Schallhorn said. “We had a program in the Navy for patients
with significant injuries to the arms and legs. LASIK can have a very
positive impact on their quality of life,” he said.
Continuing study of LASIK in military patients, such as fighter pilots,
will continue to show the procedure’s limits, said Drs. Schallhorn
and Tanzer. “War fighters go into austere environments and hot,
dirty places. We’re conscious of that and seek the most safe and
effective procedure in the safest manner possible,” Dr. Tanzer
said.
Dr. Tanzer reported at the FDA meeting some results from LASIK studies
conducted in the Navy. For example, he said, of 250,000 procedures to
date, to his knowledge, all but one patient were able to return to full-duty
status. Some may say that LASIK has such stunning results in the military
because patients tend to be younger; however, with an average surgical
age of 32 in the Navy compared with 36 for the general population, the
difference is not all that vast, Dr. Tanzer said.
Patients with extreme hyperopia and myopia are generally excluded from
LASIK because of poor results—that said, the end visual results
in these patients continues to be an area of interest. “Although
these areas are understudied, you’d have to have new techniques
and technology to make them viable for LASIK,” Dr. Schallhorn said. “The
extreme levels have not been well studied. Given the small number of
studies and outcomes, a lot of surgeons are not opting to do LASIK anymore
in extreme patients.”
Dr. Lindstrom echoed those thoughts. “I almost never do +4 [in
hyperopes] and in myopes, I rarely do over –10,” he said.
His parameters are more conservative than what many lasers are approved
for. In cases where patients want to take the surgical risk, he’ll
operate on only one eye at a time to make sure patients are satisfied
with the results.
More often, Dr. Lindstrom steers extreme myopes toward a phakic IOL and
extreme hyperopes toward refractive lens exchange to ensure better results
and higher patient satisfaction.
That said, some recent research is further exploring LASIK in extreme
groups. In a study published this year in the Journal of Cataract & Refractive
Surgery, Dimitri T. Azar, M.D., field chair of ophthalmologic research
and head, Department of Ophthalmology and Visual Sciences, and professor,
University of Illinois Eye and Ear Infirmary, Chicago, found that LASIK
in patients with –6 to –10 D of myopia was safe, although
efficacy and predictability were slightly lower.
Dr. Azar said that he continues to analyze and report LASIK results in
unique patient groups, including another recently published study regarding
LASIK in patients between the ages of 40 and 69. These kinds of studies
help offer patients solid pre-op predictions about surgical outcomes,
Dr. Azar said.
Technology, a speedy visual recovery
Naturally, surgeons want to know that new technology and techniques—be
it wavefront-guided LASIK or an approach such as sub-Bowman’s keratomileusis
(SBK)—are safe and equally, if not more, effective compared with
their original procedure. This is an area that will always merit further
research, Dr. Schallhorn said.
For example, studies of ultra-thin flaps such as those made during SBK
may attract special attention in the future. “For most folks with
the femtosecond laser, the average flap is 100 microns, but can we do
80 microns? Right now, we really can’t. As the technology improves,
can we make an 80-micron flap, and does it result in better outcomes?
We’ll need to look at the implications of that,” he said.
Improved contrast sensitivity and the unintentional creation of higher-order
aberrations are two other technology-related areas that surgeons would
like to see explored.
Some ophthalmologists also would like the procedure to have an even faster
visual recovery—so fast, perhaps, that one might liken it to a
dentist appointment, Dr. Durrie said. “We need to look at getting
vision to 20/20 in an hour. It’s possible with the phakic IOLs,” he
said.
Studies related to visual recovery could help determine whether military
patients such as aviators can return to their work after one or two weeks
instead of the current one-month wait, Dr. Schallhorn said.
Ultimately, the results from safety and efficacy studies should boost
patient satisfaction with the procedure and give surgeons better information
to present to patients during pre-op discussions, Dr. Lindstrom said.
Editors’ note:
Dr. Durrie has financial interests with Advanced Medical Optics
(AMO, Santa Ana, Calif.) and Alcon (Fort Worth, Texas), among
other ophthalmic companies. Dr. Lindstrom has financial interests
with AMO, Alcon, and Bausch & Lomb (Rochester, N.Y.), among other
ophthalmic companies. Dr. Schallhorn has financial interests with AMO.
Drs. Azar and Tanzer have no financial interest related to their comments.
Contact
Information
Azar: 312-996-6590, dazar@uic.edu
Durrie: 913-491-3330,
ddurrie@durrievision.com
Lindstrom: 612-813-3633,
rllindstrom@mneye.com
Schallhorn: 619-920-9031,
scschallhorn@yahoo.com
Tanzer: David.Tanzer@med.navy.mil |